Risk of COVID-19 reinfection and its severe complications in adults treated with long-term opioids for chronic non-cancer pain
Main Article Content
http://orcid.org/0000-0003-3939-8979
Michael Partin, MD
http://orcid.org/0000-0002-7496-6604
Grace Hwang
http://orcid.org/0009-0008-3610-5214
Christopher Heron, MD
http://orcid.org/0000-0002-8245-2953
Kyle Burke, MD
http://orcid.org/0009-0006-6322-8995
Adriana Von Rago
http://orcid.org/0009-0002-8027-0838
Aleksandra E. Zgierska, MD, PhD
http://orcid.org/0000-0002-7773-6003
Abstract
Introduction: With the sequelae of the COVID-19 pandemic, many concerns remain about reinfection and waning immunity against the virus and its variants.
Objective: This study aimed to assess the risk of COVID-19 reinfection and its severe complications in adults treated with long-term opioid therapy (LTOT) for chronic non-cancer pain.
Methods: A retrospective cohort study was conducted using the TriNetX database of over 2,120,701 adults infected by COVID-19 between January 2020 and June 2022. The reinfection was defined as a new COVID-19 infection recorded after at least 30 days after the initial one. Logistic regression was applied to evaluate the probability of reinfection and severe COVID-19 illness (measured by emergence department (ED) visits, hospitalization, intensive care unit (ICU) care, or death) within 30 days of the reinfection, controlled for baseline demographic and comorbid conditions.
Results: The study included 36,265 adults treated with LTOT. Adults on LTOT, compared to those without LTOT, were 2.8 times more likely to have a COVID-19 reinfection, and, after re-infected, were 1.4-1.6 times more likely to be admitted to ED, hospital, and ICU, though no impact was found on a 30-day mortality.
Conclusion: the study findings can help guide clinical decisions about the level of monitoring and care for adults treated with LTOT for chronic non-cancer pain who experience a COVID-19 reinfection. Future prospective research is needed to fully understand the components of risk and optimal risk mitigation strategies of COVID-19 reinfection in adults on LTOT.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Shanthanna H, Nelson AM, Kissoon N, Narouze S. The COVID-19 pandemic and its consequences for chronic pain: a narrative review. Anaesthesia. 2022;77(9):1039-1050. doi:10.1111/anae.15801
3. Lavin A, LeBlanc F, El Helou A. The impact of COVID-19 on chronic pain. Front Pain Res Lausanne Switz. 2023;4:1234099. doi:10.3389/ fpain.2023.1234099
4. Consonni M, Telesca A, Grazzi L, Cazzato D, Lauria G. Life with chronic pain during COVID-19 lockdown: the case of patients with small fibre neuropathy and chronic migraine. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2021 ;42(2):389-397. doi:10.1007/s10072-020-04890-9
5. Lacasse A, Pagé MG, Dassieu L, et al. Impact of the COVID-19 pandemic on the pharmacological, physical, and psychological treatments of pain: findings from the Chronic Pain & COVID-19 Pan-Canadian Study. Pain Rep. 2021;6(1):e891. doi:10. 1097/PR9.0000000000000891
6. Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet Lond Engl. 2011; 377(9784):2226-2235. doi:10.1016/S0140-6736(11 )60402-9
7. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;1 8(12):1166-1175. doi:10.1002/pds.1833
8. Zgierska AE, Burzinski CA, Garland EL, et al. Experiences of adults with opioid-treated chronic low back pain during the COVID-19 pandemic: A cross-sectional survey study. Medicine (Baltimore). 2023;102(41):e34885. doi:10.1097/MD.0000000000034885
9. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30-39. doi:10.1038/s41380-020-00880-7
10. Wang Q, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry Off J World Psychiatr Assoc WPA. 2021;20(1):124-130. doi:10.1002/wps.20806
11. Jamali Z, Emamian MH, Hashemi H, Fotouhi A. The Association of Opioid Use Disorder and COVID-19, a Longitudinal Study. Int J Prev Med. 2022;13:157. doi:10.4103/ijpvm.ijpvm_68_22
12. Dahan A, Aarts L, Smith TW. Incidence, Reversal, and Prevention of Opioid-induced Respiratory Depression. Anesthesiology. 2010;112 (1):226-238. doi:10.1097/ALN.0b013e3181c38c25
13. Wiese AD, Grijalva CG. The use of prescribed opioid analgesics & the risk of serious infections. Future Microbiol. 2018;13(8):849-852. doi:10.2217 /fmb-2018-0101
14. Schimmel J, Manini AF. Opioid Use Disorder and COVID-19: Biological Plausibility for Worsened Outcomes. Subst Use Misuse. 2020;55(11):1900-1901. doi:10.1080/10826084.2020.1791184
15. Ren X, Zhou J, Guo J, et al. Reinfection in patients with COVID-19: a systematic review. Glob Health Res Policy. 2022;7(1):12. doi:10.1186/s4125 6-022-00245-3
16. SeyedAlinaghi S, Mirzapour P, Dadras O, et al. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. Eur J Med Res. 2021;26(1):51. doi:10.1186 /s40001-021-00524-8
17. Dhillon RA, Qamar MA, Gilani JA, et al. The mystery of COVID-19 reinfections: A global systematic review and meta-analysis. Ann Med Surg 2012. 2021;72:103130. doi:10.1016/j.amsu.2 021.103130
18. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022;28(11):2398-2405. doi:10.1038/s41 591-022-02051-3
19. Tuan WJ, Spotts H, Zgierska AE, Lennon RP. COVID-19 outcomes among adult patients treated with long-term opioid therapy for chronic non-cancer pain in the USA: a retrospective cohort study. BMJ Open. 2021;11(11):e056436. doi:10.11 36/bmjopen-2021-056436
20. Shah R, Kuo YF, Baillargeon J, Raji MA. The impact of long-term opioid use on the risk and severity of COVID-19. J Opioid Manag. 2020;16(6) :401-404. doi:10.5055/jom.2020.0597
21. Yek C, Warner S, Wiltz JL, et al. Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021. MMWR Morb Mortal Wkly Rep. 2022;71(1):1 9-25. doi:10.15585/mmwr.mm7101a4
22. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLOS Med. 2015;12(10):e10 01885. doi:10.1371/journal.pmed.1001885
23. Latronica JR, Clegg TJ, Tuan WJ, Bone C. Are Amphetamines Associated with Adverse Cardiovascular Events Among Elderly Individuals? J Am Board Fam Med JABFM. 2021;34(6):1074-1081. doi:10.3122/jabfm.2021.06.210228
24. Tuan WJ, Sehgal N, Zgierska AE. Using electronic health record’s data to assess daily dose of opioids prescribed for outpatients with chronic non-cancer pain. Fam Med Community Health. 2021;9(Suppl 1):e001277. doi:10.1136/fmch-2021-001277
25. Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc JAMIA. 2011;18(4):441-448. doi:10.1136/amiajnl-2011-000116
26. Khani S, Tafaroji J, Yaghoubi M, Emami Kazemabad MJ, Hejazi SA. Prevalence of COVID-19 outcomes in patients referred to opioid agonist treatment centers. Front Pharmacol. 2023;14:1105 176. doi:10.3389/fphar.2023.1105176
27. U.S. Centers for Disease Control and Prevention. COVID-19 and Your Health. Centers for Disease Control and Prevention. February 11, 2020. Accessed March 6, 2022. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
28. Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci U S A. 2015;112(49):15078-15083. doi:10.1073/pn as.1518393112
29. Abrams EM, Szefler SJ. COVID-19 and the impact of social determinants of health. Lancet Respir Med. 2020;8(7):659-661. doi:10.1016/S221 3-2600(20)30234-4